Eliana Merle Barclays Bank PLC, Research Division. Great. Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Ionis here wi ...

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.’s (NASDAQ:IONS) ION582 for Angelman syndrome (AS), a rare neurological ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and ...

In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 ...

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best performers on Tuesday. Ionis Pharmaceuticals soared to a ...

Leerink Global Healthcare Conference 2026 March 9, 2026 3:40 PM EDTCompany ParticipantsBrett Monia - Founder, CEO ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...

We recently published 10 Stocks Leaving the Market in the Dust. Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is one of the best performers on Wednesday. Ionis Pharmaceuticals extended its winning streak ...

CEO Brett Monia told investors at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company received FDA acceptance of its supplemental NDA for olezarsen in severe ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The ...